May 13, 2026

How Should Public Biotechs Best Announce Positive Clinical Data?

Positive clinical data is the lifeblood of every public biotech. It is the culmination of years of scientific effort and represents an all too infrequent opportunity to raise much needed capital for the trial’s sponsor.

Yet time and again, I see companies underwhelm. A press release goes out. A call is held. The stock barely moves. And management is left wondering why the reaction failed to match their perceived “importance” of the result.

Announcing positive data is not just about disclosure. It is about context, choreography, and conviction. What follows is a practical framework for how public biotechs should think about announcing positive data.

1. Telegraph your data and its importance ahead of time.

Long before your trial reads out, you should have narrowed your guidance on the timing from half a year to a quarter. Then, in the quarterly financial results you publish before the readout, you might even narrow the timing to a given month.

Telegraphing when you will announce data creates anticipation. Numerous analysts publish research notes that chronologically list upcoming data readouts – and the easier it is for them to slot you into their calendar, the greater the chance you have of being included.

Then, be it at a healthcare investor conference, KOL event, or analyst/investor or R&D-day, you should carefully set expectations for what success would look like:

• Detail the metrics you intend to share and why they are important ahead of time.
• If there are drugs already approved for the indication you’re going after, make sure your analysts and investors know the efficacy/safety profile of each, and a viable range for where your drug candidate could fit in.

Be conservative – both in terms of timing and an initial efficacy/safety profile of your drug candidate. In this sense, you should hope to under promise and overachieve.

2. Hold a call. Have slides. Quote experts. Make a big deal about it.

If the data you’ve generated is positive, treat it as such. That means holding a conference call, sharing slides, and signaling – explicitly – that this is an important inflection point for the company.

Too many biotechs rely on a press release alone, assuming that sophisticated investors will “figure it out.” Some will. Many won’t. Analysts and investors cover dozens upon dozens of names simultaneously. If you don’t elevate the moment yourself, you are implicitly telling the market that it doesn’t matter.

A call with slides does four things:

• It slows the market down (from reaching a snap decision).
• It allows you to frame the data in your own words.
• It gives analysts and investors a common reference point.
• It enables analysts to hear the congratulations or concerns of other analysts – during Q&A – before they publish research notes on your results.

In your press release, it’s customary to include quotes from your lead investigator(s) – individuals you may even provide access to on the conference call you host (or unilaterally with interested analysts and investors afterwards).

For this to work effectively, each KOL must be intimately familiar with your data and be chaperoned by management. This is typically achieved by a confidential teach-in with your KOL faculty before the data is made public, and by the provision of coaching and/or a Q&A cheat sheet.

Depending on the timing of your announcement, you may choose to bring your analysts “over the wall” ahead of time (e.g. over the preceding weekend) so that they can publish immediately after you have made the data public. Note: not all banks allow their analysts to be wall-crossed and that you will also likely be encroaching on your analysts’ weekends. Nevertheless, wall-crossing analysts may be especially important if you are considering a financing on the back of your data.

3. Assume that everyone is new to your story.

Management teams live with their data for days/weeks before it is announced. Investors do not.

What feels obvious internally – why this endpoint matters, how this compares to historical controls, why a modest numerical difference is clinically meaningful – often requires explanation externally.

The most common mistake I see on data calls is starting too far into the weeds. Start with an overview – and don’t feel that this is stealing the thunder from later in the call:

• Characterize your success right off the bat.
• Explain the unmet need.
• What did we hope to see?
• And why does what we saw matter?

Then you can get into the data, repeat your key talking points again, and talk about next steps.

Be mindful that investors are not buying what you just announced; they are buying what comes after. If you don’t clearly articulate how this data advances the program – from a regulatory, clinical, or strategic standpoint – you leave the market to fill in the blanks. And it usually does so more conservatively than you would.

4. Remember your first reaction to your data.

This is the golden rule I try to impress upon my clients.

Whatever your first reaction was when you were first unblinded to or shown your data – disappointment in a secondary endpoint, confusion over the lack of a dose-dependent response, insufficient context to determine just how good the data really is – that is also likely to be the first reaction of your investors and analysts.

Do not lose sight of that as you work your way further through the data in the days that follow, and present up front any mitigating facts or data to help people get comfortable with your results in an accelerated timeframe.

5. Be prepared to talk about your peers.

Positive data never exists in a vacuum. It is immediately compared – fairly or unfairly – to peers, competitors, and adjacent programs, regardless of whether or not your trial was a head-to-head comparison (it seldom is).

Management teams often try to avoid these comparisons on calls – trying too hard to just report solely on their own data. That is a mistake. Analysts will make the comparison anyway; it is  better that it is framed accurately by you (with the appropriate legal caveats) than by others unfairly comparing apples and oranges.

Remember: you don’t need to disparage competitors or already approved drugs, but you do need to be able to explain:

• How your data compares on efficacy, safety, convenience, or durability.
• Where cross-trial comparisons are appropriate – and where they are not.
• Why your approach is differentiated, even if headline numbers appear similar.

If you are not prepared to discuss peers, it suggests either a lack of confidence, a lack of awareness, or a lack of preparation. None of that reassures the market.

6. Make certain the call itself goes well.

This sounds obvious, but it is astonishing how often it is ignored.

A data call should be scripted and rehearsed. Not to make it artificial – but to make it clear and compelling. Transitions should be deliberate. Responsibilities should be obvious. Slides should tell a story, not just display numbers.

Remember: this call may be replayed, excerpted, quoted, and relied upon for months or even years. Treat it accordingly and rehearse the script and Q&A multiple times. Yes, every management team hates rehearsing, but it is genuinely an exceptionally good investment of everyone’s time. A bad call – filled with uncomfortable silences, presenter mispronunciations and slip-ups, typos on slides, bad quality audio, etc., – drastically undermines good data. A good call materially amplifies it.

7. Give people a reason to keep holding your stock.

Data announcements often attract short-term capital. And that capital can leave just as quickly as it arrives if there is no reason for it to stay.

Be explicit about what comes next, generally when a next milestone is anticipated, and its importance. Specifically, you should detail:

• Upcoming planned regulatory interactions.
• Additional near-term data readouts.
• Trial initiations.
• High-level thoughts about partnering opportunities (if relevant).
• Other approaching commercial milestones.

None of this is about hype. It is about visibility. Long-only investors in particular want to understand what keeps the story moving forward over the next 3, 6, and 12 months.

Give people a reason to hold your stock, rather than sell it on the back of your positive data and buy back in before your next big announcement.

8. Outreach after the data: sequence matters.

For calls: analysts first, investors and journalists second.

• Analysts are the interpreters; they write the research notes that frame how the broader market understands what has happened. Giving them early access – within the constraints of Regulation FD – is paramount in getting your story out accurately and quickly.
• Investor calls then build on that foundation. Reach out to your top holders and also the top targets of your investor outreach program. It’s also important to respond in a timely fashion to incoming requests for calls with management, since those investors self-select in the best possible way.
• Embargoed outreach to journalists should have taken place ahead of time, but if not (or if there was insufficient interest), journalist calls can be slotted in between investor calls.

9. Financing considerations: think early, not after the fact.

Positive data often opens a financing window. That is both an opportunity and a risk.

You should be consulting your bankers before the data announcement about:

• Whether a raise makes sense at all.
• Whether a confidentially marketed deal is preferable to a traditional follow-on.   
• The best timing for an announcement (pre-market vs post-market) to give a financing the best possible momentum/chance.
• The most appropriate financial vehicle (traditional follow-on, ATM usage, convert issuance, private placement, etc.).

In my experience, bankers and new investors prefer a confidentially marketed deal, as it typically gives them greater certainty over execution and a cheaper entry point, respectively.

Conversely, companies and existing shareholders usually prefer to announce their data first and price a traditional follow-on afterwards, which creates more execution uncertainty but, potentially, also less dilution.

Ultimately, market conditions and the strength of the data are the two biggest factors in determining which route a biotech takes.  

Finally, biotechs should ensure ahead of time that their Board – or a subset of it, such as a pricing committee – is primed. Nothing slows momentum like internal indecision at the moment the market is paying attention. To that end, even if you are only considering tapping your ATM, or only responding to reverse inquiries, be clear internally, in advance, about the minimum price you are prepared to accept.

10. Let the positive clinical data live on your IR website for a good amount of time.

While most webcasts are taken down within 90-180 days of their first transmission/replay, and most investor presentations are replaced as soon as a new one has been filed with the SEC, positive clinical data represent a seminal moment in a biotech’s history – and the materials surrounding its first disclosure become foundational documents for any future prospect trying to get up to speed ahead of a potential investment.

As such, leave a PDF of the clinical data slides on your IR website indefinitely, as well as the webcast replay link, alongside a PDF of the press release announcing the data. Keeping it all in one place makes it incredibly easy for a new investor or analyst to navigate.

The appropriate time to take down the materials would be upon regulatory approval (in the case of pivotal data) or when later stage trial data becomes available (Phase 3 data superseding Phase 2 data, for example).